Retatrutide (20 mg Vial) Dosage Protocol

Retatrutide is a triple-receptor agonist (GLP-1 / GIP / glucagon) studied in Phase 2 trials for body-weight reduction up to 24% at 48 weeks. It is among the most potent incretin compounds in clinical investigation. This page covers the 20 mg vial.

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: Once weekly  |  Half-life: ~6 days

Standard Approach (2 mL = 10.00 mg/mL)

Reconstituting with 2 mL bacteriostatic water produces a concentration of 10.00 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Reconstitution Steps

1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
2. Draw 2 mL of bacteriostatic water into a sterile syringe.
3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
4. Gently swirl until fully dissolved. Do not shake.
5. Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 8 mg per dose, once weekly (1 dose/week).

Protocol Overview

Retatrutide is positioned at the high end of the incretin landscape. Phase 2 trial protocols call for slow titration over 12+ weeks before reaching maintenance, with each step held for 4 weeks to allow GI tolerability. The compound has no validated "aggressive" or accelerated path — every clinical trial uses the same paced ramp.

Most research protocols run 24–48 weeks of continuous use. Body-weight changes typically begin in weeks 4–8 and continue progressively through 48 weeks. Plateauing usually occurs at 60–80% of the maximum effect by week 24 in trial data; the remaining benefit comes between weeks 24–48.

Cycle length: Most users run 24-week or 48-week cycles. After cessation, weight regain is the norm without lifestyle anchoring (protein, resistance training, sustainable caloric intake). Some protocols transition to a maintenance dose (e.g., reducing from 8 mg to 4 mg weekly) rather than full cessation.

What to expect by week: Weeks 1–4 — appetite suppression begins, mild GI side effects. Weeks 5–12 — visible weight loss starts, GI side effects diminish at each new step. Weeks 13–24 — steady weight reduction, energy patterns normalize. Weeks 24+ — maintenance phase, focus shifts to body composition.

Dosing Protocol

The standard Phase 2 protocol uses a 4-week-per-step titration. Each step is held for 4 weeks before considering escalation:

• Weeks 1–4: 2 mg once weekly. Manages first-exposure GI side effects. Do not escalate if nausea/vomiting persist.
• Weeks 5–8: 4 mg once weekly. First "real" therapeutic dose; weight-loss curve begins.
• Weeks 9–12: 6 mg once weekly. Continue if previous step was tolerated.
• Weeks 13+ (maintenance): 8 mg once weekly. The Phase 2 maximum. Some users hold at 4 or 6 mg if 8 mg produces excessive appetite suppression.

Hold-and-reassess: If GI side effects become limiting at a step, hold that dose for an additional 2–4 weeks before considering further escalation. Skipping a step is not validated — it produces severe nausea in most users.

Day-of-week timing: Choose a fixed day each week (e.g., Saturday morning). Consistency matters because the half-life is ~6 days. Doses can be shifted ±48 hours without disrupting the steady state.

Missed dose: If a dose is missed by ≤72 hours, take it when remembered and resume the regular schedule. If >72 hours, skip and resume on the next scheduled day.

De-escalation: When tapering off, drop one step every 2 weeks rather than stopping abruptly to ease the appetite-suppression rebound.

Storage Instructions

Important Notes

How This Works

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — the only triple-agonist in clinical trials. GLP-1 activation slows gastric emptying and enhances satiety. GIP augments insulin secretion in response to glucose and modulates lipid metabolism. The glucagon-receptor component drives an increase in energy expenditure absent from dual or single agonists.

The molecule is fatty-acid acylated to bind albumin in serum, slowing renal clearance and enabling once-weekly dosing. The combined three-receptor profile produces greater body-weight reduction in trials than any prior incretin compound.

Potential Benefits & Side Effects

Potential Benefits

• Phase 2 obesity trial: up to 24% weight reduction at 48 weeks (8 mg).
• Phase 2 type-2 diabetes: HbA1c reductions up to 2.0% with substantial weight loss.
• Triple receptor activation drives both appetite suppression and increased energy expenditure.
• Improvements in lipid profile and liver fat content reported alongside weight loss.

Side Effect Profile

• Nausea (most common, dose-dependent — typically resolves with the 4-week titration hold).
• Vomiting and diarrhea, particularly during titration steps.
• Decreased appetite (target effect; can become limiting at higher doses).
• Fatigue and headaches reported during early weeks.
• Heart-rate elevation observed in some trial participants.

Lifestyle Factors

• Hydrate aggressively — incretin agonists slow gastric emptying and reduce thirst signaling.
• Prioritize protein (1.0–1.6 g/kg/day) to preserve lean mass during rapid weight loss.
• Resistance training 2–3×/week is critical to maintain muscle.
• Limit high-fat meals immediately after dosing — fatty foods amplify nausea.
• Smaller, more frequent meals are better tolerated than large meals.
• Sleep 7–9 hours/night — sleep loss blunts GLP-1 efficacy on appetite.

Injection Technique

• Inject subcutaneously into abdomen (avoid 2-inch radius around navel), outer thigh, or upper arm.
• Rotate injection sites every dose to prevent lipohypertrophy.
• 90° angle with short (4–8 mm) insulin syringes.
• Bring vial to room temperature 15 min before injecting.
• Hold 5 seconds after full plunger depression before withdrawing.